文献速递脑血管病外科神经重症

脂蛋白相关磷脂酶A2水平及其早期变化对动脉瘤性蛛网膜下腔出血患者迟发性脑缺血的预测评估

Assessment of lipoprotein-associated phospholipase A2 level and its changes in the early stages as predictors of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage.
PubMed 文献 · J Neurosurg · 2019-01-18

该前瞻性观察队列研究纳入114例动脉瘤性蛛网膜下腔出血患者,检测入院时、住院第1天和第2天晨间血清脂蛋白相关磷脂酶A2水平,发现43例(37.72%)发生迟发性脑缺血,入院时脂蛋白相关磷脂酶A2>200 μg/L是迟发性脑缺血的强预测因子(OR 6.24,95%CI 2.05-18.94,p=0.001)。

要点

  • 入院时脂蛋白相关磷脂酶A2>200 μg/L是迟发性脑缺血的强预测因子(OR 6.24)。
  • 脂蛋白相关磷脂酶A2从入院时183.06 μg/L降至第2天167.24 μg/L(p=0.040)。
  • 入院时脂蛋白相关磷脂酶A2预测迟发性脑缺血的AUC为0.710。

核心结论

  • 迟发性脑缺血患者血清脂蛋白相关磷脂酶A2水平显著升高,且在入院后2天内下降。
  • 动脉瘤性蛛网膜下腔出血早期脂蛋白相关磷脂酶A2水平可能是迟发性脑缺血发生的新型预测生物标志物。

研究设计与样本

  • 前瞻性观察队列研究,纳入114例动脉瘤性蛛网膜下腔出血患者。
  • 采用商品化酶联免疫吸附试验试剂盒测定入院时(D0)、住院第1天晨间(D1)和第2天晨间(D2)的血清脂蛋白相关磷脂酶A2水平。

主要发现

  • 43例(37.72%)患者发生迟发性脑缺血。
  • 平均血清脂蛋白相关磷脂酶A2从D0的183.06±61.36 μg/L降至D1的175.32±51.49 μg/L(D0 vs D1,p=0.303)和D2的167.24±54.10 μg/L(D0 vs D2,p=0.040)。
  • 脂蛋白相关磷脂酶A2水平变化(D0-D1和D0-D2)在迟发性脑缺血组与无迟发性脑缺血组间相当。
  • 控制WFNS分级(OR 3.35,95%CI 1.18-9.51,p=0.023)和改良Fisher分级(OR 6.07,95%CI 2.03-18.14,p=0.001)后,D0脂蛋白相关磷脂酶A2>200 μg/L是迟发性脑缺血的强预测因子(OR 6.24,95%CI 2.05-18.94,p=0.001)。
  • WFNS分级(AUC=0.792)、改良Fisher分级(AUC=0.731)和D0脂蛋白相关磷脂酶A2(AUC=0.710)均为迟发性脑缺血的强预测因子,三者预测效能相当(WFNS分级 vs 脂蛋白相关磷脂酶A2:p=0.233;改良Fisher分级 vs 脂蛋白相关磷脂酶A2:p=0.771)。

关键数值与推荐

  • 入院时(D0)脂蛋白相关磷脂酶A2>200 μg/L预测迟发性脑缺血的OR为6.24(95%CI 2.05-18.94,p=0.001)。
  • WFNS分级预测迟发性脑缺血的AUC为0.792,改良Fisher分级AUC为0.731,D0脂蛋白相关磷脂酶A2 AUC为0.710。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The relationship between lipoprotein-associated phospholipase A2 (Lp-PLA2) and various cardiovascular and cerebrovascular diseases is inconsistent. However, the connection between Lp-PLA2 level and delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (aSAH) remains unclear. The objective of this study was to investigate the relationships between the Lp-PLA2 levels in the early stages of aSAH and the occurrence of DCI. METHODS: The authors evaluated 114 patients with aSAH who were enrolled into a prospective observational cohort study. Serum Lp-PLA2 level at admission (D0), on the first morning (D1), and on the second morning of hospitalization (D2) were determined using commercial enzyme-linked immunosorbent assay kits. The relationship between Lp-PLA2 levels and DCI was analyzed. RESULTS: Forty-three patients with aSAH (37.72%) experienced DCI. Mean serum Lp-PLA2 level decreased from 183.06 ± 61.36 μg/L at D0 (D0 vs D1, p = 0.303), to 175.32 ± 51.49 μg/L at D1 and 167.24 ± 54.10 μg/L at D2 (D0 vs D2, p = 0.040). The Lp-PLA2 level changes (D0-D1 and D0-D2) were comparable between patients with and without DCI. Multivariate model analysis revealed Lp-PLA2 level (D0) > 200 μg/L was a more significant factor of DCI compared with Lp-PLA2 (D1) and Lp-PLA2 (D2), and was a strong predictor of DCI (odds ratio [OR] 6.24, 95% confidence interval [CI] 2.05-18.94, p = 0.001) after controlling for World Federation of Neurosurgical Societies (WFNS) grade (OR 3.35, 95% CI 1.18-9.51, p = 0.023) and modified Fisher grade (OR 6.07, 95% CI 2.03-18.14, p = 0.001). WFNS grade (area under the curve [AUC] = 0.792), modified Fisher grade (AUC = 0.731), and Lp-PLA2 level (D0; AUC = 0.710) were all strong predictors of DCI. The predictive powers of WFNS grade, modified Fisher grade, and Lp-PLA2 (D0) were comparable (WFNS grade vs Lp-PLA2: p = 0.233; modified Fisher grade vs Lp-PLA2: p = 0.771). The poor-grade patients with Lp-PLA2 (D0) > 200 μg/L had significantly worse DCI survival rate than poor-grade patients with Lp-PLA2 (D0) ≤ 200 μg/L (p < 0.001). CONCLUSIONS: The serum level of Lp-PLA2 was significantly elevated in patients with DCI, and decreased within the first 2 days after admission. Lp-PLA2 in the early stages of aSAH might be a novel predictive biomarker for the occurrence of DCI.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Ding CY, Cai HP, Ge HL, et al. Assessment of lipoprotein-associated phospholipase A2 level and its changes in the early stages as predictors of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg. 2019. PMID: 30660116. doi:10.3171/2018.8.JNS181839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。